NMDA receptor antagonists for depression: Critical considerations

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Glutamate dysfunction, specifically N-methyl-D-aspartate receptor (NMDAR) abnormalities, is implicated in major neuropsychiatric disorders.
• Increased glutamatergic activity may contribute to depression pathophysiology.
• NMDAR antagonists are being investigated for antidepressant effects, but underlying molecular mechanisms require clarification.

Purpose of the Study:

• To review the current literature on the role of NMDAR antagonists in major depression.
• To investigate the potential of NMDAR antagonists as a novel antidepressant strategy.

Main Methods:

• A critical literature review was conducted.
• The focus was on studies examining NMDAR antagonists and their effects in major depression.

Main Results:

• NMDAR antagonists, exemplified by ketamine, offer a promising rapid treatment for treatment-resistant depression, unlike traditional antidepressants.
• These agents may promote neuroplasticity, neurogenesis, and neurotransmitter release.
• Transient adverse events, such as dissociative symptoms, currently limit ketamine's use.

Conclusions:

• Targeting NMDARs with antagonists presents a viable alternative for major depression treatment.
• The therapeutic actions of NMDAR antagonists may vary depending on their specific brain region localization.